Characterization of the methemoglobin forming metabolites of benzocaine and lidocaine.
1. Topical anesthesia with benzocaine or lidocaine occasionally causes methemoglobinemia, an uncommon but potentially fatal disorder where the blood has a reduced ability to transport oxygen. Previous in vitro studies using human whole blood have shown that benzocaine causes more methemoglobin (MetHb) formation than lidocaine, and that both compounds require metabolic transformation to form the MetHb producing species. In the current investigation, the active species of benzocaine forming the MetHb was investigated. 2. HPLC analysis of benzocaine samples incubated with human hepatic S9 showed the formation of a peak with the same UV spectrum and retention time as benzocaine hydroxylamine (BenzNOH). To confirm the activity of BenzNOH, MetHb production following exposure to the compound was determined in whole human blood using an Avoximeter 4000 CO-oximeter. 3. BenzNOH produced MetHb in a concentration dependent manner without the need for metabolic activation. Benzocaine in the presence of metabolic activation required a concentration of 500 μM to produce a similar degree of MetHb formation as 20 μM BenzNOH without activation. Previous work suggested that two metabolites of lidocaine may also form MetHb; N-hydroxyxylidine and 4-hydroxyxylidine. Of these two metabolites 4-hydroxyxylidine produced the most MetHb in whole blood in vitro in the absence of metabolic activation, however BenzNOH produced up to 14.2 times more MetHb than 4-hydroxyxylidine at a similar concentration. 4. These results suggest that the ability of benzocaine to form MetHb is likely to be mediated through its hydroxylamine metabolite and that this metabolite is inherently more active than the potentially MetHb-forming metabolites of lidocaine.
a Division of Applied Regulatory Science , FDA/CDER/OTS/OCP , Silver Spring , MD , USA and.
Neil
N
Hartman
a Division of Applied Regulatory Science , FDA/CDER/OTS/OCP , Silver Spring , MD , USA and.
Hongfei
H
Zhou
a Division of Applied Regulatory Science , FDA/CDER/OTS/OCP , Silver Spring , MD , USA and.
Jinzhe
J
Mao
b Division of Pharmaceutical Analysis , FDA/CDER/OPS/OTR , Silver Spring , MD , USA.
Daniel
D
Mans
b Division of Pharmaceutical Analysis , FDA/CDER/OPS/OTR , Silver Spring , MD , USA.
Michael
M
Boyne
a Division of Applied Regulatory Science , FDA/CDER/OTS/OCP , Silver Spring , MD , USA and.
Vikram
V
Patel
a Division of Applied Regulatory Science , FDA/CDER/OTS/OCP , Silver Spring , MD , USA and.
Thomas
T
Colatsky
D000082:Acetaminophen / Q000031:analogs & derivatives; D000779:Anesthetics, Local / Q000378:metabolism; D001566:Benzocaine / Q000378:metabolism*; D006801:Humans; D008012:Lidocaine / Q000378:metabolism*; D008706:Methemoglobin / Q000378:metabolism*; D008708:Methemoglobinemia
D000779:Anesthetics, Local; D000082:Acetaminophen; C045360:2,6-dimethylacetaminophen; D008706:Methemoglobin; D008012:Lidocaine; D001566:Benzocaine
Carboxylesterase; N-methyl transferase; cytochrome P450; methemoglobinemia